DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j8x99f/fsh_signaling) has announced the addition of the "FSH Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity of the p38 MAPK, ERK, and PI3K signaling cascades. FSH majorly induces steroidogenesis and is involved in the normal growth and function of reproductive organs in mammals.
There are today 187 companies plus partners developing 259 FSH pathway targeting drugs in 1021 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 135 drugs.
Fsh Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 147 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 145 out of the 147 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 35 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
- Includes more than 187 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
- Lists commercial, generic and code names for drugs.
- This Drug Pipeline Update contains 259 FSH pathway targeting drugs in development, which have a total of 1021 developmental projects in cancer. In addition there are suspended and ceased drugs.
- Included FSH pathway targeting drugs are also in development for 146 other indications, where of 106 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 26
- Registered # 1
- Pre-registration # 3
- Phase III # 28
- Phase II # 95
- Phase I # 120
- Preclinical # 123
- No Data # 3
- Suspended # 2
- Ceased # 135
For more information visit http://www.researchandmarkets.com/research/j8x99f/fsh_signaling